Sulforaphane Synergizes With PD-1 Blockade Through Activating CD8+ T Cells in Non-Small Cell Lung Cancer: Preclinical and Clinical Investigations
{{output}}
Anti-PD-1/PD-L1 therapy has achieved promising success across several tumor types; however, its efficacy is still far from satisfactory in non-small cell lung cancer (NSCLC). Combining therapies have been attempted to synergize anti-PD-1/PD-L1 therapy through ... ...
